First FDA-Approved RNA Therapy Targets Severe Hypertriglyceridemia to Cut Pancreatitis Risk

A metabolic disorder characterized by dangerously high blood fat levels and life‑threatening pancreatic complications now has its first FDA‑approved treatment—an RNA‑targeting therapy from Ionis Pharmaceuticals.

On Wednesday, the FDA approved olezarsen (marketed as Tryngolza) for use with diet and exercise in adults suffering from severe hypertriglyceridemia (sHTG). The agency cleared two dosing regimens, delivered monthly via an auto‑injector. Ionis, headquartered in Carlsbad, California, anticipates the therapy will be commercially available starting in July.

In sHTG, triglyceride levels—a type of blood fat—climb to hazardous concentrations. This chronic condition arises from a mix of obesity, lifestyle habits, and genetic predisposition, elevating the risk of various cardiovascular issues. The gravest complication is acute pancreatitis, a sudden pancreatic inflammation that triggers severe abdominal pain necessitating hospital care. Ionis estimates that roughly three million Americans live with sHTG.

Tryngolza works by reducing hepatic production of apoC‑III, a liver protein that governs triglyceride metabolism. As an antisense oligonucleotide, it binds to apoC‑III messenger RNA, prompting its degradation and thereby lowering apoC‑III levels. This reduction is intended to enhance triglyceride clearance from the bloodstream.

The FDA’s decision relied on data from two Phase 3 trials. Participants receiving the drug experienced up to a 72% reduction in fasting triglyceride levels versus placebo at six months, an effect maintained through 12 months. The therapy also cut acute pancreatitis events by as much as 91%. The most frequent adverse events were injection‑site reactions and elevated liver enzymes; the label recommends monitoring hepatic enzymes. Full trial results were published earlier this year in the New England Journal of Medicine.

Tryngolza received its initial FDA approval in 2024 for familial chylomicronemia syndrome (FCS), a rare inherited subtype of sHTG. This patient group is far smaller than the broader sHTG population, numbering roughly 3,000 individuals in the United States, most of whom remain undiagnosed, according to Ionis.

Ionis disclosed $107.5 million in Tryngolza sales for 2025 under the FCS indication. The company forecasts $100 million to $110 million in sales for the current year, but the expanded sHTG market offers a more robust growth trajectory. In an investor briefing, Ionis suggested that peak annual sales could surpass $3 billion.

Growth potential for Tryngolza is central to Ionis’s strategy. Historically, Ionis has collaborated with larger partners to advance and commercialize its RNA‑targeting assets, earning royalties on sales. The company’s primary revenue stream remains Biogen’s royalties from Spinraza, its spinal muscular atrophy therapy.

In recent years, Ionis has pivoted toward retaining and commercializing its own discoveries. Tryngolza for FCS marked the first drug the company brought to market independently. Last year, Ionis added a second self‑commercialized product with the FDA’s approval of Dawnzera, an antisense oligonucleotide designed to prevent swelling episodes in hereditary angioedema.

William Blair analysts Myles Minter and John Boyle noted in a research note that Tryngolza’s sHTG approval was anticipated, given the robust trial data. They observed that the subdued stock response could reflect investor attention on forthcoming results from Arrowhead Pharmaceuticals’ siRNA therapy Redemplo, which last year became the second approved FCS treatment. Key Phase 3 readouts for Redemplo in sHTG are slated for the third quarter of this year.

Upon its FCS launch, Tryngolza carried a list price of $595,000 per year. Ionis has since reduced the annual cost to $40,000, a move analysts believe will not materially impact the company’s financial outlook.

“Tryngolza’s entry into the sHTG market should drive substantial growth, building on the performance seen in its FCS launch and the pancreatitis‑risk reduction data already available,” the William Blair analysts wrote. “We expect prescribing volume to more than compensate for the price adjustment, as evidenced by management’s raised peak‑sales forecast from above $2 billion to above $3 billion.”

Photo by Ionis Pharmaceuticals

Source link